RESUMO
In the realm of petrochemical operations, persistent efforts have been made to curtail specific energy consumption; however, certain heat sources continue to be underutilized. This paper investigates the condition of a Lurgi methanol plant to identify process streams with enough wasted heat that have the potential to produce electricity. After a thorough analysis, one particular zone is identified where an air cooler package and seawater exchanger are used to decrease the temperature of crude methanol vapor. To harness this untapped heat for electricity generation, an organic Rankine cycle (ORC) is proposed. In the quest for efficient electricity production, three distinct working fluids-dry (R600a), wet (R134a), and isentropic (R11)- are scrutinized to compare their performance in generating electricity within the ORC system. In addition, the maximum amount of electricity that can be generated from this waste heat recovery (WHR) project is determined and optimized using a multi-objective optimization method. By leveraging genetic algorithms, the system's exergy is enhanced while minimizing costs. A comprehensive economic comparison is conducted using probability analysis to evaluate each system's financial viability. The results show that dry and isentropic working fluids yield the best results for electricity production, generating approximately 9-10 MW. The return on investment (ROI) for these working fluids is also nearly similar, at 16 %. Among the chosen working fluids, R600a is selected as the superior option due to its lower outlet temperature for crude methanol. Additionally, because the cooling water flow for the condenser of the ORC is identified as a limitation in the current petrochemical plant, a new optimization is conducted with a constraint on the flow of cooling water, aiming for approximately 3000 tons/h. The results show that the proposed WHR-ORC system can generate a maximum of approximately 7.5 MW net electricity in the studied petrochemical plant, while also reducing CO2 emissions by up to 40,000 tons per year. The innovative methodology showcased in this research underscores its economic viability, paving the way for heightened energy efficiency and environmentally conscious methanol production practices.
RESUMO
Extramedullary spread of multiple myeloma was thought to be uncommon but with recent advancements in imaging and increased patient survival, the incidence of the extraosseous disease has risen in living individuals. Despite this, the extraosseous spread of multiple myeloma has been under-diagnosed and under-reported. Timely diagnosis of this extraosseous disease is clinically important, as it indicates a more aggressive disease variant and carries a poor prognosis.
RESUMO
Treatment options are limited for multiple myeloma patients who have developed four/five drug-refractory disease. Selinexor (Sel) and belantamab mafodotin (belamaf) were recently approved by the US FDA for treatment of RRMM. The toxicity profile of these drugs is a concern since these agents are used in patients who have already undergone multiple lines of treatment. In this review, we discuss the toxicity profile and strategies for the management of toxicities of Sel and belamaf for the treatment of RRMM. We conducted a comprehensive literature search on PubMed, Embase, Cochrane, and Clinicaltrials.gov using the terms "selinexor", "belantamab", "belamaf", and "multiple myeloma" without applying any limitations based on the date of the study, language, or country of origin. The most common hematological toxicity associated with these two drugs is thrombocytopenia. Cytopenias, constitutional symptoms, gastrointestinal effects, and hyponatremia are the major toxicities of Sel. Keratopathy and anemia are the major toxicities of belamaf. Treatment modifications and dose interruption are usually needed when side effects are more than grade II. As these are newer drugs with limited data, continuous surveillance and monitoring are warranted during the treatment course with early mitigation strategies.